SCHEMBL704656

SCHEMBL704656

CC(=O)NC12CC3CC(C1)C(N1C[C@]4(c5ccc(F)cc5)CCCN4C1=O)C(C3)C2

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 3/20 0.35
HSD11B1 P28845 2/20 0.34
RAB9A P51151 2/20 0.33
EPHX2 P34913 4/20 0.33
CNR2 P34972 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC6A9 P48067 4/20 0.32
OPRM1 P35372 1/20 0.32
KCNH2 Q12809 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
FKBP1A P62942 1/20 0.32
CCR3 P51677 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704845 0.84 HSD11B1 (0.45) HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL704844 0.84 HSD11B1 (0.45) HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL708177 0.84 HSD11B1 (0.45) HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL705638 0.84 HSD11B1 (0.37) ALDH1A1HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL707431 0.83 HSD11B1 (0.36) ALDH1A1HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL704768 0.82 HSD11B1 (0.43) HSD11B1
SCHEMBL705801 0.82 HSD11B1 (0.43) HSD11B1
SCHEMBL16457046 0.80 HSD11B1 (0.33) HSD11B1SLC6A9OPRM1KCNH2
SCHEMBL704657 0.80 ALDH1A1 (0.36) ALDH1A1L3MBTL1NPC1HSD11B1RAB9A
SCHEMBL704980 0.74 HSD11B1 (0.40) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP claimed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US claimed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP claimed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO claimed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US claimed
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 ALDH1A1 97/4885L3MBTL1 4305/4885NPC1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.